A three-judge panel on the Fifth U.S. Circuit Court of Appeals late Friday issued a temporary nationwide injunction blocking doctors from prescribing the abortion pill mifepristone through telehealth and barring its delivery by mail, reinstating a requirement that the drug be prescribed and dispensed in person at clinics. The ruling hands a significant legal win to Louisiana, which sued the FDA over Biden-era rules that the state argued funneled abortion pills past its ban on elective abortion.
The decision overrides a lower court ruling from earlier this month that had paused the lawsuit while the Trump administration's FDA conducts a safety review of the drug. Now, unless the Supreme Court intervenes, women seeking mifepristone anywhere in the country must obtain it in person, a return to the dispensing standard that was in place before the FDA permanently lifted the in-person requirement in 2023.
Judge Stuart Kyle Duncan wrote the opinion for the panel, concluding that Louisiana demonstrated irreparable harm because remote access to mifepristone directly undermines the state's prohibition on elective abortion. The court found Louisiana was likely to succeed on the merits of its challenge and that the lower court erred in denying immediate relief.
The ruling's language was direct. As The Hill reported, the panel wrote:
"Every abortion facilitated by FDA's action cancels Louisiana's ban on medical abortions and undermines its policy that 'every unborn child is human being from the moment of conception and is, therefore, a legal person.'"
The court also pointed to concrete financial harm. Louisiana cited Medicaid costs, including $92,000 spent treating two women in 2025 for complications the state says were caused by mail-order abortion pills, as part of its standing argument. Duncan found that persuasive.
The panel went further, questioning the adequacy of the FDA's own safety analysis. In a passage that should trouble anyone who trusts federal regulators to do their homework, the court stated:
"The public interest is not served by perpetuating a medical practice whose safety the agency admits was inadequately studied. Indeed, the public interest demands the opposite."
That is a remarkable sentence. A federal appeals court is saying, in plain English, that the FDA itself acknowledged gaps in its safety review, and that the public deserves better than a regulatory shrug. For years, abortion-rights advocates have insisted that mifepristone's safety profile is beyond question. The Fifth Circuit's panel clearly disagrees with that framing, and it cited the FDA's own admissions to make the point.
This is not a ruling that affects only states with abortion bans. Telehealth prescribing of mifepristone has become common even in states where abortion remains legal. AP News reported that the decision reaches well beyond Louisiana because it eliminates the mail-order pipeline everywhere, not just in pro-life jurisdictions.
That nationwide scope is what makes the ruling so consequential. Mifepristone is one of two drugs commonly used in medication abortions. The Biden administration's 2023 decision to permanently drop the in-person dispensing requirement turned mail-order abortion into a booming practice, one that effectively allowed women in states with abortion bans to circumvent those laws from their living rooms.
Louisiana argued exactly that. The state's case rested on a straightforward claim: the FDA's loosened rules made it easier for abortion pills to be mailed into states where abortion is banned, rendering those bans unenforceable. The Fifth Circuit agreed. Federal appeals courts have become central battlegrounds in the nation's most contentious policy fights, and this case is no exception.
Louisiana Attorney General Liz Murrill did not mince words. Breitbart reported that Murrill declared the ruling a "Victory for Life!" and issued a blistering statement:
"The Biden abortion cartel facilitated the deaths of thousands of Louisiana babies (and millions in other states) through illegal mail-order abortion pills. Today, that nightmare is over."
That language reflects the depth of frustration in pro-life states that watched for years as the Biden administration's FDA systematically dismantled safeguards around mifepristone. For officials like Murrill, the mail-order pipeline was not a neutral policy choice, it was a deliberate end-run around state law.
Abortion-rights groups reacted swiftly. Brittany Fonteno, CEO of the National Abortion Federation, said in a statement:
"Make no mistake: this ruling is not grounded in science or patient safety. It is a politically-driven decision that overrides medical expertise and years of research, and threatens to upend how abortion care is delivered nationwide."
Sen. Patty Murray (D-Wash.) called the consequences "devastating and immediate," adding that "mifepristone is safe and effective, millions of women have used this medication since the FDA approved it over 25 years ago." Murray argued that the only reason mifepristone faces heavy regulation is "anti-abortion politics, not because of science."
But those claims run headlong into the court's own finding, that the FDA admitted its safety review was inadequate. If the science were as settled as Murray and Fonteno insist, the FDA's own concession would not exist. The panel did not invent a safety concern out of thin air. It pointed to the agency's own words.
The broader pattern is familiar. Progressive officials and advocacy groups treat regulatory shortcuts as settled law when they produce outcomes the left favors, then cry foul when courts apply ordinary legal scrutiny. Louisiana has found itself at the center of major court battles before, and Democrats have not always handled the results gracefully.
The ruling sets up a likely appeal to the Supreme Court. Danco Laboratories, which manufactures mifepristone, asked for a one-week pause so it could seek emergency relief from the justices, calling the order "unprecedented" and warning of "immediate chaos."
Whether the Supreme Court takes up the case, and how quickly, will determine whether the in-person requirement holds or gets stayed. The justices have dealt with mifepristone litigation before, and this latest round will test whether the court is willing to let a sweeping appellate injunction stand while the underlying legal questions are resolved.
Meanwhile, the Trump administration's FDA is still conducting its own safety review of the drug. The lower court had paused the lawsuit to let that review proceed. The Fifth Circuit overrode that pause, finding that Louisiana's harm was too immediate to wait. The order still allows the FDA's review to continue, but the mail-order pipeline is shut down in the interim.
Federal courts continue to serve as the decisive arena for the country's biggest policy disputes. Whether the issue is redistricting challenges or abortion regulation, the pattern holds: when the political branches overreach, the judiciary steps in.
For pro-life Americans, the ruling represents something they have waited years to see: a federal court willing to say that loosening drug-safety rules to expand abortion access has real consequences, and that states have standing to push back. Louisiana's argument was not abstract. It pointed to actual Medicaid costs, actual complications, and actual circumvention of state law.
For the abortion-rights movement, the ruling is a direct challenge to the post-Dobbs strategy of using telehealth and mail-order prescriptions to maintain access regardless of state-level bans. That strategy depended on the FDA's 2023 rule change holding up in court. It did not.
ACLU lawyer Julia Kaye warned that the decision "is going to affect patients' access to abortion and miscarriage care in every state in the nation." That framing treats the prior mail-order regime as the baseline. But the prior baseline, the one that existed before 2023, required in-person prescribing and dispensing. The Fifth Circuit simply restored it.
The appellate courts have shown a willingness to correct lower-court overreach when the facts demand it. This case fits that mold.
When a federal agency loosens safety rules under political pressure, and a state can show real harm from that decision, the courts are supposed to act. The Fifth Circuit did exactly what the system is designed to do, and the people who built the mail-order workaround are the ones who should have seen it coming.